Suppr超能文献

美国血液透析血管通路的利用、通畅性和相关并发症。

Utilization, patency, and complications associated with vascular access for hemodialysis in the United States.

机构信息

Division of Vascular Surgery, Johns Hopkins Medical Institutions, Baltimore, Md; Division of Vascular Surgery, University of South Florida, Tampa, Fla.

Division of Vascular Surgery, Johns Hopkins Medical Institutions, Baltimore, Md; Division of Transplant Surgery, University of California San Francisco, San Francisco, Calif.

出版信息

J Vasc Surg. 2018 Oct;68(4):1166-1174. doi: 10.1016/j.jvs.2018.01.049.

Abstract

BACKGROUND

This study examines the utilization and outcomes of vascular access for long-term hemodialysis in the United States and describes the impact of temporizing catheter use on outcomes. We aimed to evaluate the prevalence, patency, and associated patient survival for pre-emptively placed autogenous fistulas and prosthetic grafts; for autogenous fistulas and prosthetic grafts placed after a temporizing catheter; and for hemodialysis catheters that remained in use.

METHODS

We performed a retrospective study of all patients who initiated hemodialysis in the United States during a 5-year period (2007-2011). The United States Renal Data System-Medicare matched national database was used to compare outcomes after pre-emptive autogenous fistulas, preemptive prosthetic grafts, autogenous fistula after temporizing catheter, prosthetic graft after temporizing catheter, and persistent catheter use. Outcomes were primary patency, primary assisted patency, secondary patency, maturation, catheter-free dialysis, severe access infection, and mortality.

RESULTS

There were 73,884 (16%) patients who initiated hemodialysis with autogenous fistula, 16,533 (3%) who initiated hemodialysis with prosthetic grafts, 106,797 (22%) who temporized with hemodialysis catheter prior to autogenous fistula use, 32,890 (7%) who temporized with catheter prior to prosthetic graft use, and 246,822 (52%) patients who remained on the catheter. Maturation rate and median time to maturation were 79% vs 84% and 47 days vs 29 days for pre-emptively placed autogenous fistulas vs prosthetic grafts. Primary patency (adjusted hazard ratio [aHR], 1.26; 95% confidence interval [CI], 1.25-1.28; P < .001) and primary assisted patency (aHR, 1.36; 95% CI, 1.35-1.38; P < .001) were significantly higher for autogenous fistula compared with prosthetic grafts. Secondary patency was higher for autogenous fistulas beyond 2 months (aHR, 1.36; 95% CI, 1.32-1.40; P < .001). Severe infection (aHR, 9.6; 95% CI, 8.86-10.36; P < .001) and mortality (aHR, 1.29; 95% CI, 1.27-1.31; P < .001) were higher for prosthetic grafts compared with autogenous fistulas. Temporizing with a catheter was associated with a 51% increase in mortality (aHR, 1.51; 95% CI, 1.48-1.53; P < .001), 69% decrease in primary patency (aHR, 0.31; 95% CI, 0.31-0.32; P < .001), and 130% increase in severe infection (aHR, 2.3; 95% CI, 2.2-2.5; P < .001) compared to initiation with autogenous fistulas or prosthetic grafts. Mortality was 2.2 times higher for patients who remained on catheters compared to those who initiated hemodialysis with autogenous fistulas (aHR, 2.25; 95% CI, 2.21-2.28; P < .001).

CONCLUSIONS

Temporizing catheter use was associated with higher mortality, higher infection, and lower patency, thus undermining the highly prevalent approach of electively using catheters as a bridge to permanent access. Autogenous fistulas are associated with longer time to catheter-free dialysis but better patency, lower infection risk, and lower mortality compared with prosthetic grafts in the general population.

摘要

背景

本研究在美国调查了血管通路在长期血液透析中的利用情况和结局,并描述了临时导管使用对结局的影响。我们旨在评估预先放置自体动静脉瘘和移植物、临时导管后放置的自体动静脉瘘和移植物以及仍在使用的血液透析导管的流行率、通畅率和相关患者生存率。

方法

我们对在美国进行血液透析的所有患者进行了回顾性研究,研究时间为 5 年(2007-2011 年)。我们使用美国肾脏数据系统-医疗保险匹配的全国数据库来比较预先放置自体动静脉瘘、预先放置移植物、临时导管后放置自体动静脉瘘、临时导管后放置移植物和持续导管使用的结果。结果包括主要通畅率、主要辅助通畅率、次要通畅率、成熟、无导管透析、严重通路感染和死亡率。

结果

有 73884 例(16%)患者开始血液透析时使用自体动静脉瘘,16533 例(3%)患者开始血液透析时使用移植物,106797 例(22%)患者在使用自体动静脉瘘前临时使用血液透析导管,32890 例(7%)患者在使用移植物前临时使用导管,246822 例(52%)患者仍在使用导管。成熟率和中位成熟时间分别为 79%和 47 天,与预先放置的自体动静脉瘘相比,预先放置的移植物为 84%和 29 天。与移植物相比,自体动静脉瘘的主要通畅率(调整后的危险比[aHR],1.26;95%置信区间[CI],1.25-1.28;P<0.001)和主要辅助通畅率(aHR,1.36;95%CI,1.35-1.38;P<0.001)均显著更高。在 2 个月后,自体动静脉瘘的次要通畅率更高(aHR,1.36;95%CI,1.32-1.40;P<0.001)。与自体动静脉瘘相比,移植物的严重感染(aHR,9.6;95%CI,8.86-10.36;P<0.001)和死亡率(aHR,1.29;95%CI,1.27-1.31;P<0.001)更高。临时使用导管与死亡率增加 51%(aHR,1.51;95%CI,1.48-1.53;P<0.001)、主要通畅率降低 69%(aHR,0.31;95%CI,0.31-0.32;P<0.001)和严重感染增加 130%(aHR,2.3;95%CI,2.2-2.5;P<0.001)相关,与使用自体动静脉瘘或移植物相比。与使用自体动静脉瘘开始血液透析的患者相比,仍使用导管的患者死亡率高 2.2 倍(aHR,2.25;95%CI,2.21-2.28;P<0.001)。

结论

临时导管的使用与更高的死亡率、更高的感染率和更低的通畅率相关,从而破坏了将导管作为永久通路的桥梁的普遍做法。与移植物相比,自体动静脉瘘在一般人群中与更长的无导管透析时间但更好的通畅率、更低的感染风险和更低的死亡率相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验